1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Zhejiang Anglikang Pharmaceutical Co. Ltd. Class A

Zhejiang Anglikang Pharmaceutical Co. Ltd. Class A

SSZSE:002940
23.94
CNY
-1.36
(-5.38%)
0.92EPS
33.92P/E
5.33BMarket Cap
Zhejiang Anglikang Pharmaceutical Co. Ltd. Class A
SZSE:002940
(Shenzhen Stock Exchange)

Recent

price

23.94

P/E

ratio

33.92

div

yld

0.05%

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
4.79
5.46
4.74
6.16
8.4
7.39
6.78
6.91
7.89
8.11
7.66
7.04
7.01
Revenue per Share
0.35
0.45
0.58
0.71
0.73
0.59
0.86
0.6
0.64
0.69
0.4
0.62
0.78
Basic EPS, GAAP
0.01
0.73
0.82
1
0.44
0.73
0.57
0.55
0.58
0.76
0.79
0.96
- -
Free Cash Flow per Basic Share
0.53
0.15
0.21
0.32
0.01
0.36
0.47
0.24
0.17
0.31
0.29
0.28
0.01
Dividend per Share
1.27
1.74
2.19
2.61
4.86
5.1
6.54
6.64
7.45
7.86
7.59
8.07
8.2
Book Value per Share
0.93
1.42
1.88
2.31
4.64
4.9
6.36
6.33
7.15
5.48
5.15
5.65
5.81
Tangible Book Value per Share
142
142
142
142
149
189
190
200
199
201
201
202
196
Basic Weighted Avg Shares
682
774
672
873
1,255
1,396
1,290
1,380
1,568
1,626
1,538
1,425
1,376
Sales/Revenue/Turnover
9.3
10.42
15.77
15.51
9.58
10.8
15.81
11.71
9.25
13.31
10.61
14.25
17.24
Operating Margin (%)
34
36
34
33
39
38
42
46
61
79
88
77
- -
Depreciation Expense
50
64
82
101
109
112
164
120
127
138
80
125
153
Net Income, GAAP
17.27
14.72
14.96
14.65
11.39
17.72
13.97
18.14
10.18
11.65
4.09
13.06
13.36
Effective Tax Rate (%)
7.36
8.27
12.24
11.58
8.66
8.04
12.69
8.68
8.12
8.51
5.22
8.8
11.1
Profit Margin (%)
-76
-30
17
59
594
622
848
781
663
830
655
673
764
Working Capital
32
38
9
- -
- -
- -
- -
- -
150
424
304
242
272
LT Debt
217
264
327
394
971
1,016
1,378
1,475
1,646
1,832
1,798
1,867
1,902
Total Equity
- -
10.75
16.11
22.93
15.81
12.62
15.04
9.87
7.62
8.45
6.56
6.91
7.82
Return on Invested Capital (%)
- -
17.43
19.28
21.91
13.4
9.81
12.17
6.89
7.41
4.81
1.05
4.58
5.83
Return on Capital (%)
- -
29.92
29.44
29.69
16.86
11.92
14.34
9.02
8.96
8.96
5.16
7.94
9.54
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
207
282
140
LT Borrowings
242
289
272
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
202
202
202
Market Capitalization
6,762
6,397
5,328

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,486
1,666
1,537
Cash, Cash Equivalents & STI
790
891
835
Accounts Receivable, Net
176
140
113
Inventories
447
512
520
Total Current Liabilities
813
904
773
Payables & Accruals
- -
- -
- -
ST Debt
207
282
140
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
26.28%
6.39%
3.83%
Free Cash Flow
13.48%
13.08%
22.02%
Net Income, GAAP
11.03%
0.47%
56.15%
Sales/Revenue/Turnover
7.57%
2.31%
-7.35%
Total Cash Common Dividend
343.23%
-0.28%
-1.99%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
408
439
274
416
1,538
2025
346
379
- -
370
1,425
2026
340
287
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.2
-0.09
0.15
0.4
2025
0.08
0.26
- -
0.24
0.62
2026
0.09
0.19
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.23
0.02
0.02
0.29
2025
0.14
0.04
- -
-0.21
0.28
2026
0.01
0.16
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Zhejiang AngLiKang Pharmaceutical Co., Ltd. focuses on the manufacturing and commercialization of pharmaceutical raw materials, finished drug products, and specialized empty capsules. The company's diverse portfolio includes offerings for anti-infective treatments, notably oral cephalosporins, along with medications for cardiovascular health, digestive system ailments, and respiratory conditions. AngLiKang also actively pursues drug discovery and development, with a particular emphasis on innovative therapies for central nervous system disorders, kidney-related conditions, and enhancing its cardiovascular and oral cephalosporin lines. Founded in 2001 and headquartered in Shengzhou, China, the firm continues to expand its reach, recently entering into strategic partnerships for advanced biopharmaceutical development and securing market approvals for new pain relief and antibiotic raw materials.